Latest / Stock Movers / Merck Reports; Big Tech Earnings; Marvell-Lumentum Latest
Transcript
- 0:02Speaker 1: Bloomberg Audio Studios, podcasts, radio, news.
- 0:08Speaker 2: The Stock Movers Report, your roundup of companies making moves
- 0:12Speaker 2: in the stock market, harnessing the power of Bloomberg data.
- 0:15Speaker 1: Let's take a look at some stocks on the move today.
- 0:18Speaker 1: I'm Nathan Hager, joined by Bloomberg's Dan Curtis on another
- 0:21Speaker 1: morning where some big names are reporting earnings, including Eli Lilly. Dan,
- 0:27Speaker 1: Being the obesity leader means something.
- 0:30Speaker 2: Good morning.
- 0:31Speaker 3: Good morning. It means 4% of the stock this morning,
- 0:34Speaker 3: which is how much the shares are gaining under ticker LLY.
- 0:38Speaker 3: The company raises its full year guidance. It now sees
- 0:41Speaker 3: adjusted EPS for the period $ 35 to $ 36 per share.
- 0:46Speaker 3: That's up 50 cents from the previous range. That comes
- 0:49Speaker 3: after a third quarter top and bottom line beat. And
- 0:53Speaker 3: as you said, it's getting fat off of getting thin.
- 0:55Speaker 3: Is that bound Manjaro revenue coming in ahead of estimate?
- 0:59Speaker 3: So big news in that space.
- 1:02Speaker 1: Getting fat off of getting thin.
- 1:03Speaker 2: I'm going to use that. Thank you, Dan.
- 1:05Speaker 1: Eli Lilly is the only big drug maker to report earnings.
- 1:09Speaker 1: We also heard from Merck this morning.
- 1:10Speaker 3: That's right. And that's also up 2% ticker MRK. And
- 1:15Speaker 3: this company has really been looking into the oncological, that's
- 1:18Speaker 3: the cancer treatment space. The company as well, raising full
- 1:21Speaker 3: year profit forecast, third quarter top and bottom lines also beat.
- 1:25Speaker 3: And this is coming down to a blockbuster cancer drug
- 1:28Speaker 3: called Keytruda. That's helping to fuel the growth. Merck is
- 1:31Speaker 3: also defending the franchise with a version called Keytruda Culex,
- 1:35Speaker 3: and that can be ingested in less time. Those sales
- 1:38Speaker 3: also be estimates, even as some European countries have blocked
- 1:41Speaker 3: the sale of the treatment. So a lot of hype
- 1:44Speaker 3: around this space. Merck, also Moderna in generally, which has
- 1:47Speaker 3: been developing an oncological with Merck. There's been a lot
- 1:52Speaker 3: of just hype in this space, and that hype is
- 1:54Speaker 3: coming through even more this morning.
- 1:56Speaker 1: Okay, so along with the drug makers, we also heard
- 1:59Speaker 1: from Caterpillar this morning, and the stock is getting pummeled, Dan.
- 2:04Speaker 3: It is. So the stock under CAT is down 9%
- 2:07Speaker 3: in the pre-market. That's despite a third quarter bottom line
- 2:10Speaker 3: beat as the top line came in around estimates. So
- 2:15Speaker 3: the headline that really caught my attention here is, cat
- 2:19Speaker 3: sees fourth quarter moderate sales and revenue growth versus fourth
- 2:22Speaker 3: quarter 25 and then they also said that fiscal year
- 2:26Speaker 3: 26 sales and revenue bid to high teens versus 2025.
- 2:30Speaker 3: i did model this out in excel so assuming a
- 2:33Speaker 3: 17.5 growth that implies around a 20.8 billion dollar in
- 2:38Speaker 3: revenue which is actually lighter than estimates so it seems
- 2:40Speaker 3: like we're getting a little bit of a slowdown implied
- 2:43Speaker 3: in the forecast we don't have exact figures But using
- 2:46Speaker 3: some back of the napkin calculations, it looks like the
- 2:49Speaker 3: fourth quarter will be a bit softer than expected and
- 2:51Speaker 3: not really weighing on the shares this morning.
- 2:54Speaker 1: OK, apparently you're not the only one using Excel because
- 2:57Speaker 1: Microsoft is moving higher. We got earnings from them as
- 3:00Speaker 1: well as Google Parent Alphabet, and they're kind of going
- 3:02Speaker 1: in two different directions this morning.
- 3:05Speaker 3: Absolutely. And that is almost to the point, right? Microsoft
- 3:07Speaker 3: has all these revenue lines, even as it spends on AI,
- 3:10Speaker 3: and it's still free cash flow positive. So Microsoft, those
- 3:14Speaker 3: shares up 3% in the pre-market. Azure revenue, X currency
- 3:19Speaker 3: is up 48%. That beat estimates. CapEx came in at
- 3:23Speaker 3: $ 45 billion, less than estimates. A lot of that was
- 3:26Speaker 3: due to delays in the delivery of some third-party cloud capacity.
- 3:29Speaker 3: So not that they're Trying to hold back on spending
- 3:31Speaker 3: is just the spending didn't come through. But as I mentioned,
- 3:35Speaker 3: positive free cash flow there. Alphabet, on the other hand,
- 3:39Speaker 3: those shares are down 10% as concerns of AI are
- 3:43Speaker 3: eating into its core search as business take hold. So
- 3:48Speaker 3: that business grew at the slowest pace in five quarters
- 3:50Speaker 3: and accounts for nearly two thirds of total revenue. So
- 3:53Speaker 3: two sides of the AI coin this morning going in
- 3:55Speaker 3: different directions.
- 3:57Speaker 2: The Stock Movers Report from Bloomberg Radio. Check back with
- 4:01Speaker 2: us throughout the day for the latest roundup of companies
- 4:04Speaker 2: making news on Wall Street. And for the latest market-moving headlines,
- 4:08Speaker 2: listen to Bloomberg Radio Live. Catch us on YouTube, Bloomberg.com,
- 4:13Speaker 2: and on Apple CarPlay and Android Auto with the Bloomberg
- 4:16Speaker 2: Business app.